Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6030909 | 0.84 | ALDH1A1 (0.73) | KDM4ELMNADRD4DRD3KCNH2 | |
| SCHEMBL6412144 | 0.84 | KDM4E (1.00) | KDM4ELMNADRD4DRD3KMT2A | |
| SCHEMBL7420674 | 0.84 | LMNA (0.77) | KDM4ELMNADRD4DRD3KMT2A | |
| SCHEMBL15938285 | 0.81 | HTR7 (0.74) | KDM4ELMNADRD4DRD3KCNH2 | |
| SCHEMBL9374413 | 0.81 | SIGMAR1 (0.76) | LMNADRD4DRD3KCNH2SIGMAR1 | |
| SCHEMBL6031227 | 0.80 | USP2 (0.64) | KDM4ELMNAKCNH2SIGMAR1USP2 | |
| SCHEMBL6030721 | 0.78 | KDM4E (0.72) | KDM4ELMNADRD4KCNH2SIGMAR1 | |
| SCHEMBL6031039 | 0.78 | ALDH1A1 (0.71) | KDM4ELMNAKCNH2SIGMAR1KMT2A | |
| SCHEMBL10294634 | 0.77 | KCNH2 (0.69) | KCNH2SIGMAR1 | |
| Bromide SCHEMBL6575201 | 0.77 | KDM4E (0.70) | KDM4ELMNADRD4KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | DRD2, DRD4, HTR2C | KDM4E 3595/4885LMNA 3652/4885DRD4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.